Treatment of LAG-3 positive tumors

US12049503B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• James NOVOTNY · Milford, US
• Nils Lonberg · Woodside, US
• Cyrus HEDVAT · New York, US
• Raphael Clynes · West Nyack, US
• Darren LOCKE · Bordentown, US
• John P. Cogswell · Yardley, US
• Jeffrey Jackson · Collegeville, US
• Christopher Harbison · Hamilton, US
• Robin EDWARDS · Newtown, US

Key dates

• Filing date: Aug 18, 2023
• Grant date: Jul 30, 2024
• Expiry date: Aug 18, 2043

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/54
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.